Viatris Guides FY24 In Line With Estimates - Update

RTTNews | 616 dias atrás
Viatris Guides FY24 In Line With Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, healthcare company Viatris Inc. (VTRS) initiated its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.70 to $2.85 per share on total revenues between $15.25 billion and $15.75 billion.

On average, seven analysts polled by Thomson Reuters expect the company to report earnings of $2.81 per share on net sales of $15.30 billion for the year. Analysts' estimates typically exclude special items.

On Monday, the company announced that its Board of Directors approved a 2024 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 for each issued and outstanding share of the Company's common stock, payable on March 18, 2024, to shareholders of record at the close of business on March 11, 2024.

The Company also announced that its Board of Directors authorized a $1.0 billion increase to its share repurchase program and now authorizes the repurchase of up to $2.0 billion of the Company's shares of common stock.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Marcadores : VTRS
read more
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%

Viatris Announces US Commercial Launch Of RYZUMVl 0.75%

Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S.
RTTNews | 583 dias atrás
Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update

Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update

While reporting financial results for the third quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2022 to solid operating momentum despite foreign exchange headwinds and absorbing inflation impact to date.
RTTNews | 1094 dias atrás
U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

Merck (MRK), known as MSD outside of the United States and Canada, announced Thursday that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris, Inc. (VTRS) related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.
RTTNews | 1140 dias atrás
Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update

Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update

While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) trimmed its total revenue guidance for the full-year 2022 to reflect the incremental impact of foreign exchange.
RTTNews | 1185 dias atrás
U.S. Private Sector Employment Rebounds More Than Expected In October

U.S. Private Sector Employment Rebounds More Than Expected In October

Payroll processor ADP released a report on Wednesday showing private sector employment in the U.S. rebounded by more than expected in the month of October. ADP said private sector employment climbed by 42,000 jobs in October after slipping by a revised 29,000 jobs in September. Economists had expected private sector employment to rise by 25,000 jobs.
RTTNews | 1h 39min atrás